Periconception blood sugar control improves maternal and perinatal outcomes: JAMA

Canada: Reduction in blood sugar levels improves outcomes for mother and child in women having diabetes before pregnancy, suggests a recent study in the journal JAMA Network Open.

Prepregnancy diabetes increases the risk of maternal and perinatal morbidity, especially if periconception blood sugar control is suboptimal. It is not known if improving control of blood sugar level from preconception to early pregnancy and midpregnancy periods can reduce the risk of adverse maternal and perinatal outcomes. 

Alexander J. F. Davidson, Department of Medicine, University of Toronto, Toronto, Ontario, Canada, and colleagues determined whether a decline in HbA1c levels from preconception to the first half of pregnancy is associated with a lower risk of adverse outcomes for mother and child.

The population-based cohort study was performed in Ontario, Canada from 2007 to 2018. It included 3459 births among women with prepregnancy diabetes whose HbA1c was measured within 90 days preconception and again from conception through 21 weeks completed gestation (early pregnancy to midpregnancy).

Net decrease in HbA1c from preconception to early pregnancy and midpregnancy was measured. The main outcome was a congenital anomaly from birth to age 1 year. 

"Women with prepregnancy diabetes who achieve a reduction in HbA1c may have improved perinatal and maternal outcomes," wrote the authors.

"Further study is recommended to determine the best combination of factors, such as lifestyle changes and/or glucose-lowering medications, that can influence periconception HbA1c reduction," they concluded.

The study, "Association of Improved Periconception Hemoglobin A1c With Pregnancy Outcomes in Women With Diabetes," is published in the journal JAMA Network Open.

DOI: https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2774458